Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT02357381
NCT02357381CompletedNot Applicable

eNeura SpringTMS Post-Market Observational U.S. Study of Migraine

eNeura, Inc.7 sites in 1 country263 target enrollmentStarted: December 1, 2014Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
263
Locations
7
Primary Endpoint
Headache Days
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

A multi-center, prospective, non-randomized, single arm, open label, post-market, observational study to evaluate the use of the eneura, springtms system in reduction of migraine headache symptoms.

Detailed Description

A prospective, non-randomized, single arm, multi-center observational study designed to evaluate the use of the SpringTMS system in reducing the frequency of headache days.

Note: This is a NON-SIGNIFICANT RISK (NSR) study of a NON-SIGNIFICANT RISK (NSR) Device. It is a post market study of a NSR device cleared by FDA through the 510(k) pre-market notification process. The cleared indications for use are provided above. This NSR study is designed to collect information on additional applications of the SpringTMS device. These additional applications include:

  1. Use of the device to evaluate the potential for regular use of sTMS to reduce the frequency, severity, and/or duration of migraine.
  2. Delivery of additional treatments (pulses) to evaluate the acute treatment efficacy of breakthrough migraine attacks with and without aura.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients 18 to 65 years of age;
  • •Patients able to understand and communicate in English;
  • •Migraine with or without aura;
  • •4-25 headache days per month (confirmed by 1-month baseline diary, minimum of 5 complete headache-free days/month);
  • •Understand and willing to provide diary and survey data.

Exclusion Criteria

  • •Subjects will be excluded from participating in this trial if they meet any of the following criteria
  • •Severe co-existing disease having a life expectancy of less than 1 year;
  • •Currently involved in any other investigational clinical trials that have not completed their primary endpoint or that may interfere with the SpringTMS study results;
  • •Mental impairment or other conditions which may not allow the subject to understand the nature, significance and scope of the study and to cooperate with follow-up requirements;
  • •Known drug and/or alcohol addiction or use of illicit substances;
  • •Patients with epilepsy or history of seizure;
  • •Severe active major depression or major psychiatric illness;
  • •Concurrent use of other neurostimulation devices (Cefaly®, TENS, implantable devices);
  • •Use of Botox® within past 4 months;
  • •Extracranial nerve block (e.g. occipital, supraorbital) within past 3 months;
  • •Use of Cefaly for prevention within past month;
  • •Patients with metal containing implants as follows:
  • •The SpringTMS may not be used in patients who have metals, conductive materials, or metal-containing implants in their head, neck or upper body. Patients with implants that are affected by a magnetic field should not use the SpringTMS. Examples of such implants include:
  • •Aneurysm clips or coils • Radioactive seeds
  • •Cochlear implants • Magnetically programmable shunt valves
  • •Cerebral spinal fluid shunts • Stents
  • •Bullets or pellets lodged in the head or upper body • Metal plates, screws, staples or sutures in skull, neck, shoulders, arms or hands
  • •Filters • Metallic artificial heart valves
  • •Electrodes • Facial tattoos with metallic ink Dental implants, fillings, or other dental appliances are okay and are not affected by the device.
  • •Note: although not explicitly excluded, safety and effectiveness have not been established in pregnant women. Please defer to the judgment of the investigator when considering the eligibility of this population.

Outcomes

Primary Outcomes

Headache Days

Time Frame: 3 months

Reduction in mean headache days

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
eNeura, Inc.
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (7)

Loading locations...

Similar Trials

Recruiting
Not Applicable
US Post-Market Surveillance Study of the Surfacer SystemVenous Disease
NCT05050799Merit Medical Systems, Inc.30
Active, not recruiting
Not Applicable
GLYCAR Post Market Multicenter StudyCongenital Premature Cardiac ClosureCardiac and Great Vessel Reconstruction and RepairPeripheral Vascular Reconstruction and Repair
NCT05661981GLYCAR SA (Pty) Ltd110
Terminated
Not Applicable
directSTIM™ Deep Brain Stimulation System Post-Market Clinical Follow-up Study on Essential TremorEssential Tremor
NCT05795218Aleva Neurotherapeutics SA21
Terminated
Not Applicable
Clinical Evaluation of the TITAN™ Total Shoulder SystemArthritisArthritis, DegenerativePost-traumatic Arthrosis of Other Joints, Shoulder RegionRotator Cuff Syndrome of Shoulder and Allied DisordersJoint InstabilityJoint TraumaDislocation, ShoulderPain, ShoulderRheumatoid ArthritisFractureAvascular Necrosis
NCT03245320Smith & Nephew, Inc.50
Unknown
Not Applicable
Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release TabletsPeripheral Neuropathic Pain
NCT04171453Viatris Korea600
eNeura SpringTMS Post-Market Observational... | Clinical Trial